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ABSTRACT
Human papillomavirus induced (HPV+) cancer incidence is rapidly rising,
comprising 60–80% of oropharyngeal squamous cell carcinomas (OPSCCs); while
rare, recurrent/metastatic disease accounts for nearly all related deaths. An in vivo
pre-clinical model for these invasive cancers is necessary for testing new therapies.
We characterize an immune competent recurrent/metastatic HPV+ murine model
of OPSSC which consists of four lung metastatic (MLM) cell lines isolated from an
animal with HPV+ OPSCC that failed cisplatin/radiation treatment. These individual
metastatic clonal cell lines were tested to verify their origin (parental transgene
expression and define their physiological properties: proliferation, metastatic
potential, heterogeneity and sensitivity/resistance to cisplatin and radiation. All MLMs
retain expression of parental HPV16 E6 and E7 and degrade P53 yet are heterogeneous
from one another and from the parental cell line as defined by Illumina expression
microarray. Consistent with this, reverse phase protein array defines differences
in protein expression/activation between MLMs as well as the parental line. While
in vitro growth rates of MLMs are slower than the parental line, in vivo growth of
MLM clones is greatly enhanced. Moreover, in vivo resistance to standard therapies
is dramatically increased in 3 of the 4 MLMs. Lymphatic and/or lung metastasis
occurs 100% of the time in one MLM line. This recurrent/metastatic model of HPV+
OPSCC retains the characteristics evident in refractory human disease (heterogeneity,
resistance to therapy, metastasis in lymph nodes/lungs) thus serving as an ideal
translational system to test novel therapeutics. Moreover, this system may provide
insights into the molecular mechanisms of metastasis.

INTRODUCTION

these cases (60–80%) human papillomavirus (HPV)
is the causative agent [4]. Despite highly successful
clinical management of primary OPSCC disease
(80–90% five year survival), loco-regional spread and
distant metastasis remain the main cause of mortality
for HPV+ OPSCC patients [5–6]. These clinical findings
emphasize the need for establishing and characterizing a
physiologically relevant animal model of metastatic HPV+
OPSCC. Recent studies have increased the mechanistic

Head and neck squamous cell carcinoma (HNSCC)
is the sixth most common cancer worldwide and although
clinical therapies have improved, local recurrence and
metastasis have stagnated the overall prognosis at 50%
survival for decades [1, 2]. A subset of these cancers,
oropharyngeal squamous cell carcinomas (OPSCC), are
increasing at near epidemic rates [3]. In the majority of
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understanding of metastasis however, the lack of clinical
survival benefit underscores that this knowledge remains
incomplete. In vivo pathways governing the “invasionmetastasis cascade” [7] include: invasion, intravasation,
survival of circulating tumor cells, extravasation,
microscopic induction and subsequent macroscopic
outgrowth at a secondary site. These biologically complex
events are difficult to model in vitro; moreover, epithelialmesenchymal plasticity is profoundly influenced by nontumor cells including endothelial, fibroblasts, stromal, and
infiltrating immune cells in the tumor microenvironment
[8]. Additionally, cytokine and chemokine signals from
distant organs influence tumor cell exosome secretion,
thus establishing unique secondary organ niches capable
of sustaining metastatic tumor growth [9–10]. Thus, in
addition to yielding mechanistic insights into metastasis,
disease specific animal models that faithfully replicate
clinical disease progression as well as resistance to therapy,
and route/site of metastatic outgrowth are essential for
defining prophylactic and metastatic treatment regimens.
In this article, we characterize a new transplantable
syngeneic mouse model of metastatic HPV+ OPSCC. Four
unique metastatic cell lines were isolated from an HPV+
murine model previously described by our laboratory
[11]. The parental mouse oropharyngeal epithelial cells
stably transformed with HPV16 E6 and E7 together with
hRas and luciferase, (mEERL) and the newly derived
mEERL lung metastasis cell lines (MLMs) maintain the
cellular effects of these driver oncogenes. Notably, the
MLM cell lines possess heterotypic traits in both their
physiologic and molecular characteristics, replicating
the heterogeneity widely described of metastatic tumors
[12–13]. Additionally, these cell lines display differences
in sensitivity to standard of care treatment modalities
(cisplatin and radiation) and more aggressive growth
in vivo than their parental cells, consistent with two
common characteristics of metastatic cancers [14]. Finally,
when re-implanted in immune competent mice, the MLM
cell lines metastasize at an increased rate developing
metastatic outgrowth within a reasonable time frame
(30–40 days). Importantly, MLM metastasis mimics the
sites of spread occurring in human disease (draining
lymph nodes and lung). Finally, not only do the parental
mEERL cells share characteristics with human HPV+
OPSCCs but so do the MLM cell lines. The combination
of these characteristics suggests that this unique metastasis
model holds great translational potential for testing new
adjuvant therapies for HPV+ OPSCC.

ascites. This mouse had been injected with 1 × 106
mEERL cells [15] and treated with cisplatin/radiation
therapy (CRT): three weekly doses of cisplatin (20 mg/kg)
and x-ray radiation (8 Gy) on days 10, 17, and 24.
Although tumor volume measurements suggested the
mouse had cleared its disease, residual tumor outgrowth
became evident at day 96. Upon reaching sacrifice criteria,
post mortem dissection revealed numerous lung tumors
(Figure 1A). The lungs were removed and individual
tumors isolated. Twelve lung tumors were harvested
and tentatively named mEERL Lung Metastasis clones
(MLM). Tumors were dissociated, seeded and expanded
in vitro; five clones survived of which one, MLM#7,
senesced. The four remaining clones were epithelial
in morphology (Supplementary Figure 1) and further
characterized.

Identification of lung tumors as mEERL
metastatic clones
To verify that the MLM clones metastasized from
the originally implanted parental mEERL tumor, MLM
cell lines were assayed for mEERL transgene expression.
The parental mEERL cells stably express HPV16 E6/E7,
hRas, and luciferase. All MLM clones, except MLM#3,
harbor significant luciferase expression (p ≤ 0.001)
(Figure 1B). mEER cells (stably expressing HPV16 E6/E7
and hRas), parent to mEERL cells, served as control. PCR
for HPV16 E6, E7 and hRas confirmed their presence in
all four MLM clones (#1, #3, #5 and #10) (Figure 1C).
Primary mouse oropharyngeal epithelial (1°MOE) cells
serve as a negative control.
The oncogenic functions of HPV16 E6 and E7 in
the MLM cells were analyzed as follows. PTPBl (mouse
ortholog of the human PTPN13 phosphatase) interacts
with E6 resulting in phosphatase degradation [16]. All
MLM cell lines demonstrate PTPBl degradation similar
to the parental mEERL line. Moreover, HPV16 E6
expression correlates with loss of P53 in all the MLM
clones as in the parental mEERLs. Finally, the effect
of E7, hyperphosphorylation of Rb, occurs in all MLM
clones (Figure 1D). As expected, none of these changes
occur in the negative control, 1°MOE. Interestingly, all
MLM lines showed some degree of luciferase expression
silencing (MLM#3 silencing luciferase completely) while
retaining HPV16 E6 and E7 function. These data suggest
that luciferase expression is not necessary or required for
survival of the MLM cell lines. However, the fact that they
all retain expression of E6 and E7 suggests the absolute
requirement of these HPV oncogenes for their survival.
Taken together, the data demonstrate that the MLM clones
are true metastatic cell lines derived from the parental
mEERL tumor.

RESULTS
Isolation of tumor clones
During routine tumor measurements for a mouse
study investigating the role of HPV16 E6/E7 in OPSCC,
one animal with a late growing recurrent tumor developed
www.impactjournals.com/oncotarget
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Molecular profiles of the MLM clones show
significant tumor heterogeneity

(p ≤ 0.05, T-test with BY FDR). Only 27 genes are shared
between the two sets of DEGs. Clustering analysis of the
two sets of DEGs and the shared set demonstrates that
MLMs are distinct from their parental cell line (mEERL),
and there are also differences between the MLMs
(Supplementary Figure 2A and 2B respectively).
To discover pathways enriched in the two sets of
DEGs and the shared set, Ingenuity Pathway Analysis (IPA®,
QIAGEN Redwood City, www.qiagen.com/ingenuity) was
performed. We found many signaling pathways enriched in
the DEGs obtained from comparison between mEERL and
MLM lines (Supplementary Table 1). Signaling pathways
were also enriched in DEGs among MLMs (Supplementary
Table 2). Interestingly, some signaling pathways such as
IL-8 and Thrombin were enriched in both sets of DEGs. In
addition to signaling pathways, a variety of other pathways

Using Illumina expression microarray analysis
we asked whether the MLM lines adequately represent
the heterotypic nature of metastasis [17–18]. Principal
component analysis showed that the mEERL samples
were very distinct from MLM lines (Figure 2A). When
MLM lines were analyzed alone, significantly fewer
gene expression differences were present. However upon
subgroup analysis, the MLMs clustered equidistantly from
each other, demonstrating genetic heterogeneity among the
metastatic lines (Figure 2B).
There are 1,612 differentially expressed genes
(DEGs) among MLMs (p ≤ 0.05, ANOVA with BY FDR),
and 1,433 DEGs between the MLM and mEERL lines

Figure 1: Identification of lung tumors as mEERL lung metastasis. A C57 Bl/6 mouse previously injected with mEERL cells

presented with ascites and was dissected on day 96 after tumor injection. (A) Photograph showing lung with several metastases (arrows).
(B) Comparison of luciferase expression in mEER cells, not stably expressing luciferase, with parental mEERL line and the MLM clones.
Luciferase expression measured as relative light units (RLU) per 10 ug of lysate. Each bar represents an N = 3; values, means ± SEM.
Statistically significant differences based on ANOVA compared to mEER control: †P ≤ 0.001. Experiments were repeated three times with
similar results. (C) PCR analysis of HPV 16 E6, E7 and hRas expression in parental mEERL cells and primary mouse oropharyngeal epithelial
cells (1°MOE) compared to the MLM clones. GAPDH was used as a loading control. (D) Western blot analysis of 1° mouse oropharyngeal
epithelial cells (1°MOE) with parental mEERL cells and the MLM clones. The cellular effects of HPV16 E6 are shown in PTPBl and P53
expression. Cellular effects of HPV16 E7 are shown by levels of hyperphosphorylated Rb (pRb). β actin used as loading control.
www.impactjournals.com/oncotarget
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are enriched in DEGs among MLMs, suggesting molecular
mechanisms of heterogeneity. Finally, a collection of
degradation pathways were enriched in the 27 shared genes
(Supplementary Table 3).
Reverse phase protein array (RPPA) analysis further
validated the heterotypic nature of the MLM cell lines,
(Figure 3A) demonstrating differences in their protein
expression. In many instances MLM protein expression
differs significantly from the parental line; most strikingly
for MLM#1. Taken together, these data are consistent with
the published literature emphasizing the heterogeneity of
metastasis.

with the RPPA expression analysis of mEERL and MLM
clones and further demonstrate that not only are the MLM
clones heterogenous from their parental mEERL cells but
also from each other (Figure 3C).

Cellular physiology of the MLM clones and
parental mEERL tumor cells
To assess the physiology of the metastatic cell lines,
cellular in vitro growth rate was analyzed. Cells were
seeded at sub-confluent levels and cell number followed
over time. None of the MLM clones demonstrated
statistically different growth from the parental cells,
but they show a trend towards slower in vitro growth
as demonstrated by the doubling time (Figure 4A and
Supplementary Figure 4A). These data suggest that no
major changes in growth rate exist between the parental
mEERL cells and the MLM clones in vitro.
Since the MLM clones were harvested from a
mouse with primary tumor recurrence following standard
cisplatin radiation therapy (CRT), we tested whether
the MLM clones differ in sensitivity to these treatments
using an in vitro clonogenic assay. Interestingly, each
MLM cell line was significantly more resistant than the
parental mEERL line to the effects of cisplatin, radiation
and their combination (cisplatin p ≤ 0.01, radiation
p ≤ 0.001, and cisplatin/radiation p ≤ 0.001) (Figure 4B
and Supplementary Figure 4B). Additionally, there are
significant differences between the clones. For cisplatin
treatment, MLM#1 and #5 are more resistant than MLM#3
and #10 (p ≤ 0.01); for radiation, MLM#1 is more resistant
than MLM #3 or MLM#10 (p ≤ 0.01) with none of the
other clones showing significant differences between each
other. When cisplatin and radiation treatment modalities
are combined, MLM#1 and #5 are significantly more
resistant than MLM#3 and #10 (p ≤ 0.01) . In addition,

mEERL and MLM tumors mimic human
HNSCC tumor staining profiles
Human metastatic OPSCC samples are rarely
biopsied, making a direct molecular comparison with
the MLM clones difficult. While tissue microarrays
containing limited numbers of metastatic samples are
commercially available (US Biomax, Inc), the HPV
status of these samples is unknown limiting their utility
for our system. Thus, we validated the expression of
epithelial and tumor markers characteristic of human
HPV+ OPSCC with the mEERL model of primary disease.
HPV tumor status was confirmed by PCR for HPV16 E6
(Supplementary Figure 3). Human HPV+ OPSCCs upregulate the cell cycle protein P16 and DNA repair protein
BRCA2, yet demonstrate low expression of tyrosine kinase
receptors such as EGFR while maintaining epithelial
markers including cytokeratin and E-cadherin [19].
Immunohistochemical staining shows that similar to
human HPV+ OPSCCs, mEERL tumors retain expression
of epithelial markers (cytokeratin and E-cadherin), as
well as BRCA2 and EGFR while demonstrating increased
expression of P16 (Figure 3B). These data were correlated

Figure 2: Illumina microarray. (A) Principal component analysis of parental mEERL cells (red) compared to MLM clones (blue).
(B) Principal component analysis of the MLM clones.
www.impactjournals.com/oncotarget
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MLM clones are capable of in vivo growth and
secondary metastasis

MLM#1 and MLM#5 differ significantly from each other
with combined therapy (p = 0.001). These findings suggest
that treatment resistance accounts, at least in part, for
metastatic survival of these clones.
Invasion is often viewed as a requisite event to
metastasis [20]. Thus, we assessed the migratory and invasive
potential of the MLM clones using matrigel chambers. In
the migration assay MLM#3, MLM#5, and MLM#10 show
a significantly increased migratory capacity compared to
the parental mEERL cells (Figure 4C and Supplementary
Figure 4C) (p ≤ 0.01). Additionally, MLM#3 and MLM#5
are more migratory than MLM#1 and #10 (p ≤ 0.001). While
all of the MLM clones show slight increases in invasion,
only MLM#5 was significantly different from the parental
mEERL cells (p ≤ 0.01) (Figure 4D and Supplementary
Figure 4D). The lack of invasive differences between clones
combined with the overall low number of cells showing
migratory capacity prompted us to investigate the metastatic
potential of the MLM clones in vivo.

To begin characterizing the MLM model system
in vivo, 5 × 104 mEERL or MLM cells were implanted in
C57Bl/6 mice. Each mouse developed tumor and tumor
growth was followed until sacrifice criteria were met. In
contrast to our in vitro results (Figure 4A) MLM clones #3
and #5 grew at a vastly increased rate compared to MLM
#1, #10 or mEERL while MLM#1 and #10 only slightly
outgrew the parental line (Figure 5A). Consequently, the
increased tumor growth rate resulted in a statistically
shorter survival for MLM#3 and MLM#5 (p ≤ 0.007)
(Figure 5B).
Given the role of the immune system in recognizing
and clearing tumors in this HPV+ model of OPSCC [21],
we wondered if the difference in growth rates was due in
part to failed immune recognition of these MLM tumors.
Therefore, the study was repeated in C57Bl6/Rag1 mice

Figure 3: Protein expression in mEERL, MLMs and human HPV+ OPSCC. (A) Heat map of reverse phase protein array

analysis of parental mEERL cells and MLM clones performed in triplicate. (B) Immunohistochemical staining of normal tissue (The
Human Protein Atlas) (38), human HPV+ OPSCC and mEERL tumor for hallmark proteins of OPSCC (Keratin, E-cadherin, P16, BRCA2
and EGFR). Scale bar, 40 μm. (C) RPPA heatmap of protein expression of four markers (EGFR, BRCA2, E-cadherin and P16) analyzed in
panel B. Cytokeratin was not analyzed as it was not included in the RPPA.
www.impactjournals.com/oncotarget
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lacking functional T and B cells. Interestingly, tumor
growth and survival patterns did not differ from those in
wildtype C57Bl/6 mice (Figure 5C, 5D). Although we
cannot rule out a role of the innate immune response,
these data suggest that the increased in vivo growth rate
observed in MLM#3 and #5 is not related to evasion of an
adaptive immune response.
To assess the metastatic potential of the MLM clones,
tissue was harvested from these mice. Mice exhibiting gross
pulmonary metastasis had the primary tumor, draining

(inguinal) lymph node, and lungs sectioned and stained
for cytokeratin to visualize epithelial cells. While many
animals showed no gross evidence of metastasis (notably
no mice in MLM#5), the limited experimental duration
(due to rapid primary tumor growth) potentially obscured
identification of metastatic outgrowth. Of those mice that
did have macroscopic lung metastasis, positive nodules of
cytokeratin staining in the inguinal lymph nodes (Figure
5E) were also present suggesting the MLM lines spread
via a lymphatic route similar to the human disease [22].

Figure 4: In vitro cellular physiology in the MLM clones. (A) In vitro growth rate of the parental mEERL cells compared to the MLM clones. Growth

is shown as doubling time (calculated as DT = Tln(2)/ln(xE/xb) where DT is doubling time; T is the time period; and xE or xB is the number of cells at the
ending or beginning of the time period), each bar represents the mean ± SEM, N = 12 from three independent experiments. Differences in growth between
the clones did not show statistically significant differences based on ANOVA (ns., P = 0.192). (B) Clonogenic survival of parental mEERL cells compared
to the MLM clones. Cells were treated with 2 µM cisplatin, 4 Gy x-ray radiation or the combination of the two modalities. Experiments were repeated three
times with similar results. Each bar represents an N = 8 from two independent experiments; values, means ± SEM. Statistically significant differences at
day 6 after treatment, based on ANOVA: †P ≤ 0.01. (C) Bar graph showing cell migration and (D) invasion on Matrigel chambers. Bars represent an N = 7,
experiments were repeated 3 times with similar results; values, means ± SEM. Statistically significant differences 12 hours after seeding, based on ANOVA:
†
P ≤ 0.01.
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Together, the data demonstrate that MLM cells are not only
capable of in vivo growth but also metastasis.

reflect the MLM clones increased resistance to radiation
(Figure 4B), but also reveal differences in metastatic rate
between lines with similar radiation resistance (MLM#3
and MLM#10). Thus, in addition to their heterogeneous
growth and treatment response, the metastatic clones differ
in their ability to metastasize to the lung.

In vivo response to standard cisplatin/radiation
therapy differs between the MLM clones
Because the in vivo growth rate of the clones
differed from that observed in vitro (Figures 4A and 5A),
we asked whether the treatment resistance inherent to the
MLM cell lines in vitro would be retained in vivo. Briefly,
5 × 104 tumor cells (parental mEERL or the MLM lines)
were implanted in C57Bl/6 mice. Due to the accelerated
growth rate of the MLM clones, mice were treated with
standard CRT therapy early in the disease course, on days
4, 11, and 18. Although each mouse initially developed a
palpable tumor, as can be seen in Figure 6A–6E, all mice
in the parental mEERL (Figure 6A) and MLM #10 (Figure
6E) groups cleared their primary disease. Of the remaining
three clones, MLM#3 (Figure 6C) was the most resistant
to treatment with only a 20% survival rate, while MLM#1
(Figure 6B) and #5 (Figure 6D) demonstrated 50% and 67%
survival respectively (Figure 6F). It is notable that although
the in vitro resistance to cis/xrt is similar between MLM#3
and MLM#10 (Figure 4B), the survival response in vivo
differs significantly (p < 0.001, Figure 6F). These data not
only demonstrate that the MLM clones differ in therapeutic
resistance from the parental mEERL cells, but also
exemplify the clonal heterotypic differences in treatment
response. As in the growth rates, the resistance demonstrated
in vivo is not completely reflective of those shown in vitro.

DISCUSSION
Clinically relevant animal models must
recapitulate critical aspects of the human disease. Here,
we characterize a novel mouse model of recurrent/
metastatic HPV+ OPSCC that faithfully mimics key
aspects of: 1) heterogeneity, 2) anatomically relevant
metastasis, and 3) resistance to standard first-line CRT.
While all MLM cell lines were harvested from the lungs
of a single mouse injected with clonal parental mEERL
cells, we show that each metastatic line derived from
this animal is phenotypically distinct from the parental
line and also from each other. These differences exist not
only in gene and protein expression profiles, but also in
growth rates, resistance to CRT and metastatic potential
(Figures 2–7). Such heterogeneity is consistent with the
published literature [23–25]. Interestingly, many of the
in vitro data were not reflective of in vivo physiology.
This is likely due to the influence of factors present in the
tumor microenvironment (stromal and immune cells) that
are absent in vitro. These differences further emphasize the
need for in vivo model systems.
On the surface, heterogeneity of solid tumors and
their metastases presents a bleak outlook for cancer cures.
However, it is important to note that in this system, all
MLM cell lines retained the cellular manifestations
of HPV oncoprotein (E6 and E7) expression strongly
suggesting that these viral oncogenes drive key pathways
necessary for tumor cell survival (Figure 1C and 1D).
These data suggest that while metastatic heterogeneity
exists, it is likely that common pathways for growth and
survival are utilized. Once identified, these pathways
could be therapeutically targeted to control or eliminate
metastatic growth despite heterogeneity.
Local spread to the draining lymph nodes and
distant pulmonary metastasis (Figure 5E and Figure 7A) in
the MLM model system mirror the clinical progression for
human OPSCC [26–27]. While the percent lung metastasis
varied among the MLM lines, the finding that they all
honed to the lung suggests a shared ability to target this
organ. Further genotype and expression analyses will
help define the pathways targeting the lung and sustaining
tumor growth at this site.
Finally, this recurrent-metastatic mouse model
demonstrates resistance to standard CRT which is common
in OPSCC patients that suffer disease recurrence and
progression [28–29]. Unfortunately, recurrence poses a major
hurdle for these patients as currently the cancer therapeutic
arsenal offers little to successfully combat this complication.

MLM clones have an increased rate of metastasis
when re-implanted in mice
To define the metastatic rate of MLM cells, we
analyzed their spread to distant organs at equivalent
end- points. The accelerated growth rate of the MLM
lines in vivo necessitated that primary tumor sites be
irradiated in an attempt to prolong survival, thus allowing
sufficient time for metastatic outgrowth. Briefly, after
establishment of a palpable primary tumor, each mouse
was treated with 8 Gy radiation on days 4, 6, and 8
after tumor implantation. Tumor growth was monitored
weekly until sacrifice criteria were met in the first mouse
(day 35); at this time, tissues from all mice were collected.
Pulmonary metastasis was assessed by cytokeratin
staining, representative images are shown in Figure 7A.
Under these conditions, parental mEERL cells failed to
metastasize while all the MLM clones showed some level
of pulmonary spread with MLM#3 metastasizing in every
animal (Figure 7B). Although not statistically different
from each other, MLM#3 and MLM#5 demonstrate a
significant increase in number of metastases compared
to clones #1 and #10 (p ≤ 0.029 ) (Figure 7C). Not only
did MLM#3 show the highest rate of metastasis but also
the highest total number of metastatic tumors. These data
www.impactjournals.com/oncotarget
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Figure 5: In vivo growth of MLM clones. Parental mEERL cells and MLM clones were injected into the hind limb of mice (50,000

cells/mouse N = 5 mice/group) to assess MLM growth in vivo. (A) Tumor growth and (B) mouse survival in wild type C57Bl6 mice.
(C) Tumor growth and (D) mouse survival in immune incompetent Rag1 mice. Values (A, C) mean, ± SEM. Kaplan Meier survival plot
differences (B, D) were calculated by pairwise multiple comparison procedures (Holm-Sidak method): †P ≤ 0.01. (E) Immunohistochemical
analysis of tissues harvested from the C57Bl/6 mice, (experiment in panel A). Pan-cytokeratin staining (brown) indicates epithelial cells in
each section. 4×, inset, and 40× magnification. Scale bars represent 100 µm and 1µm respectively.
www.impactjournals.com/oncotarget
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Figure 6: In vivo response to standard cisplatin/radiation therapy. Parental mEERL cells and MLM clones were injected into
the hind limb of C57Bl6 mice (50,000 cells/mouse N = 12 mice/group). After establishment of palpable tumors, mice were treated with
IP cisplatin (20 mg/m2) and x-ray radiation (8 Gy) on days 4, 11, and 18. Individual mouse tumor growth curves for each cell line, panel
(A) mEERL, (B) MLM#1, (C) MLM#3, (D) MLM#5, and (E) MLM#10. (F) Kaplan Meier tumor free survival graph. All non-surviving
mice were sacrificed due to tumor burden at the primary (hind limb) tumor sight. Deaths not associated with tumor (death during CRT)
were censored from the data and are indicated by dots on the corresponding curve. Statistically significant differences were calculated by
pairwise multiple comparison procedures (Holm-Sidak method): †P ≤ 0.01.
www.impactjournals.com/oncotarget
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This metastatic mouse model offers the ability to test the
efficacy of drugs emerging from the therapeutic pipeline in
blocking metastasis and recurrence due to resistance. It is
important to note that this model is immune competent. This
is of particular importance to HPV+OPSCCs as the immune
system plays a significant role in tumor clearance [30]. Thus,
this model provides a system in which to test new drugs and
study their interplay with the immune system in controlling
or eliminating metastatic tumor growth.
The parental mEERL cell line exemplifies many of
the original “hallmarks of cancer” described by Hanahan
and Wienberg over a decade ago [31]. For example, the
mEERL model system possesses replicative immortality
[21], sustained proliferative signaling [32–33], resistance
to cell death (unpublished data), and evasion of growth
suppressors [34]. Moreover, two emerging hallmarks

of tumor cells [8] are also exemplified in this model
system: 1) dysregulation of cellular energetics [35] and
2) immune evasion [36]. In this report, we describe the
mEERL model’s ability to replicate the remaining cancer
hallmarks: invasion and metastasis. Together, the mEERL
and MLM models provide a system with which to study
the mechanisms driving tumor growth and metastasis as
well as providing paradigms for testing new therapies
aimed at blocking tumor progression and recurrence. The
metastatic OPSCC model in particular holds great promise
for clinical advancement in this field as currently patients
with recurring tumors have limited options. This model
not only provides an immune competent in vivo system
for drug testing but also offers a system in which to
molecularly define metastatic pathways and identify novel
targets for therapeutic intervention.

Figure 7: Metastatic potential of MLM clones. Parental mEERL cells and MLM clones were injected into the hind limb of C57Bl6

mice (50,000 cells/mouse N = 8 mice/group) and allowed to establish tumor for 4 days. The tumor was treated with 8 Gy x-ray radiation
on days 7, 9, and 11 to slow growth of the primary tumor and increase time for metastasis to develop. At day 35 all mice were sacrificed.
(A) Representative IHC image of keratin positive lung metastasis from each clone 4× magnification. Scale bars represent 100 µm.
(B) Percent of mice from each clone demonstrating lung metastasis. (C) Number of keratin positive metastases per section (7–8 mice per
group 3 independent sections/mouse); values, mean, ± SEM. Statistically significant differences at day 35 after tumor implantation, based
on ANOVA: †P ≤ 0.01.
www.impactjournals.com/oncotarget
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MATERIALS AND METHODS

buffered saline and lysed in 200 µl TRIZOL Reagent
(Life Technologies) as per the manufacturer’s directions.
RNA was purified on RNeasy Mini Column (Qiagen) and
samples were eluted in RNase free deionized water. For
RT-PCR, cDNA was generated using the Retroscript Kit
(Life Technologies). Standard PCR was performed to
assess expression of HPV16 E6, E7, Ras and GAPDH in
each sample with the indicated primers:
HPV16 E6 forward primer 5′CAAACCGTTGTGT
GATTTGTTAATTA 3′
HPV16 E6 reverse primer 5′GCTTTTTGTCCAGA
TGTCTTTGC 3′;
HPV16 E7 forward primer 5′ ATGCATGGAGATA
CACCTACATTGCATG 3′
HPV16 E7 reverse primer 5′ TTATGGTTTCTGA
GAACAGATGGGGC 3′
hRas forward primer 5′ ATGACGGAATATAAGC
TGGTGGTGG 3′
hRas reverse primer 5′ CATGGCGCTGTACTC
CTCCTG 3′
GAPDH forward 5′ GGGAAGGTGAAGGTCGG
AGT-3′
GAPDH reverse 5′ TGGAAGATGGTGATGGG
ATTTC-3′.
RNA samples were also subjected to gene expression
profiling using Illumina MouseRef-8 Expression BeadChips
(Illumina). Raw expression data were subjected to cubic
spline normalization in GenomeStudio (version 2011.1).
Principal component analysis (PCA) were performed with
Partek Genomics Suite (version 6.6) using a significance
of p < 0.01 as a threshold for gene inclusion. ANOVA and
T-test were performed using in-house R scripts, and the
significant genes were obtained using a False Discover
Rate (FDR: Benjamini–Hochberg–Yekutieli procedure) of
p < 0.05. Hierarchical clustering was performed using the
software GENESIS (version 1.7.6). These data have been
deposited in GEO (accession # GSE68935).

Cell lines, culture conditions and authentication
Primary mouse oropharyngeal epithelial cells
(MOE) from male C57Bl/6 mice were isolated and
cultured in KSFM medium (Gibco Life Technologies).
Stable MOE lines expressing HPV16 E6/E7, hRas, and
luciferase (mEERL) were previously generated and
maintained in E-media [37] [16] [15]. mEERL lung
metastasis cells (MLM) were isolated from the lungs
of a treatment failed mouse. Individual lung metastasis
were dissected, homogenized and dissociated with
2 U/mL dispase (Roche) in RPMI1640 with penicillin/
streptomycin and Fungizone (Gibco Life Technologies).
The resulting cells were washed in PBS resuspended in
E-media with Fungizone and seeded on 35 mm tissue
culture dishes. Each metastatic clone was subsequently
expanded to larger vessels, used for analysis and
cryopreserved. In this paper, we authenticate the MLM
cell lines as being derived from the parental mEERL
tumor (Figure 1). As a further indication that the MLM
cell lines are murine in origin, we are able to implant
them into immune competent syngeneic mice and observe
tumor growth (Figure 5).

Western blot
Cells were grown to 80% confluence and harvested
in lysis buffer (50 mM Tris HCl pH 7.5, 150 mM NaCl,
5 mM EDTA, 2 mN Na3VO4, 100 mM NaF, 10 mM
NaPPi, 10% glycerol, 1% Triton X-100, 17.4 µg/mL
paramethylsulfonylfluoride, 1X HALT with EDTA), 1%
Tx-100 and HALT with EDTA (Peirce). Lysates were spun
at 10,000 RPM for 15 minutes at 4°C. Tx100 soluble cell
lysates (40 µg /lane) were separated by SDS PAGE and
analyzed by western blot with the following antibodies:
PTPBl (scH300 Santa Cruz Biotechnology), P53 (1C12
Cell Signaling), pRb (sc7905 Santa Cruz Biotechnology),
and βactin (AC-74 Sigma). Standard HRP secondary
antibodies (1:10,000) and ECL reagent (Thermo) were
used for visualization with a CCD camera imaging system
(UVP).

Reverse phase protein microarray (RPPA)
Briefly, lysates from mEERL and MLM clones
were harvested from 35 mm dishes grown to 80%
confluence and shipped to: MD Anderson Core Facility –
Functional Proteomics – RPPA (http://www.mdanderson.
org/education-and-research/resources-for-professionals/
scientific-resources/core-facilities-and-services/functionalproteomics-rppa-core/index.html) for analysis. Heatmap
was generated using protein expression profiles across
samples. Proteins and samples were clustered using an
average linkage hierarchical clustering algorithm.

Luciferase expression
Luciferase expression assays were conducted on
the soluble fraction of cell lysates harvested as per the
manufacturer’s instructions (E1500 Promega). Luciferase
was measured by incubating 10 µg protein lysate with
50 µl substrate and read on a Promega GLOMAX 96
microplate luminometer.

Cell proliferation assay

PCR and Illumina microarray analysis

Cellular growth rate was determined by seeding
5000 cells per well in 12 well plates. Time points were
collected in triplicate by washing in PBS–/– with 2 mM
EDTA and harvesting with TrypLE (Life Technologies)

RNA was harvested as follows: Cells were grown to
approximately 80% confluence, rinsed with 1X phosphate
www.impactjournals.com/oncotarget
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at 24, 48, 72, and 96 hours. All replicates were counted
on a Cell Countess system (Invitrogen). Doubling times
were calculated as DT = Tln(2)/ln(xE/xB) where DT is
doubling time; T is the time period; and xE or xB is the
number of cells at the ending or beginning of the time
period, respectively.

was detected for a period of two months. Survival graphs
were calculated by standardizing for a tumor volume of
2500 mm3. Statistical analysis for the survival graphs was
performed using the log-rank test with α = 0.01.

Colony formation

All human tissues were collected with informed
consent and approval from Sanford Health IRB
(#MOD00000135).

Human subjects

Colony forming assays were conducted by plating
200 cells per well in 12 well dishes. Six hours after seeding
1000X cisplatin (Calbiochem) solubilized in DMSO was
added to a final concentration of 2 µM. Control plates
and plates receiving radiation alone were treated with
an equivalent volume of DMSO. Within 10 minutes of
cisplatin addition, 4 Gy radiation was administered to
the radiation alone or the cisplatin/radiation conditions.
Plates were returned to a 37° incubator where colonies
were allowed to grow for 6 days and subsequently fixed in
70% ethanol and stained with trypan blue in 10% ethanol.
Colonies in triplicate wells were counted on a GelCount
imaging system (OXFORD OPTRONIX) using identical
settings.

Microscopy
Paraffin embedded tissue blocks were prepared,
sectioned, and stained using standard immunohistochemical
techniques by the Sanford Molecular Pathology Core.
Briefly, paraffin embedded tissues were sectioned to 5 μm
and stained on a BenchMark® XT automated slide stainer
(Ventana Medical Systems, Inc). Ventana iView DAB
detection kit and counterstaining with hematoxylin were
used for visualization. Staining for pan-cytokeratin
(ab9377, Abcam), E-cadherin (#3195, Cell Signaling), P16
(MA5-17093, Thermo and #10883-1-AP, ProteinTech),
BRCA2 (HPA026815, Sigma), and EGFR (ab2430,
Abcam) were used to visualize tumors of epithelial origin;
exclusion of primary antibody served as the negative
control. Lung metastases from three independent sections
were manually counted on an (Olympus DP71) microscope.

Migration and invasion
Migration and invasion assays were performed
by seeding 50,000 cells per well in BD BioCoat
matrigel chambers (BD Biosciences). After 20 hours,
invading or migrating cells were fixed and stained as
per the manufacturer’s instructions and counted at
20X magnification (EVOS cell imaging system, Life
Technologies).

Statistical analysis
For statistical analysis of mircroarray data see PCR
and Illumina microarray analysis methods. All other
statistical analyses were performed using Sigma Plot 11
(Systat Software, Inc.). Survival plots were analyzed using
Kaplan-Meier survival curves and statistical significance
was determined by the log-rank test, multiple comparisons
were made with the Holm-Sidak method. For all other data
one way ANOVA with the Holm-Sidak pairwise multiple
comparison procedures were used. An alpha 0.05 was used
for all tests unless otherwise indicated.

Animal studies
All animal experiments were approved by the
Sanford Research IACUC and performed within
institutional guidelines. Four to six week old, 20–25 gm
male C57BlJ/6 mice or C57BlJ/6 Rag 1 mice (The Jackson
Laboratory) were maintained at the Sanford Research
Laboratory Animal Research Facility in accordance with
USDA guidelines. Tumors were initiated as follows:
using a 23-gauge needle mEERL or MLM cells were
implanted subcutaneously in the right hind flank of mice
(n = 10/group). For the indicated schedule, mice were
anesthetized with 87.5 mg/Kg ketamine and 12.5 mg/Kg
xylazine, and treated with 8 Gy X-ray radiation (RS2000
irradiator, RadSource Technologies, Inc. Suwanee, GA),
intraperitoneal cisplatin (CalBiochem) dissolved in
bacteriostatic 0.9% sodium chloride (Hospira Inc.) at
20 mg/m2 or the combination of both modalities. Tumor
growth was measured weekly as previously described
[15]. Animals were euthanized when tumor size was
greater than 1.5 cm in any dimension. Conversely, mice
were considered tumor free when no measurable tumor
www.impactjournals.com/oncotarget

ACKNOWLEDGMENTS
We thank Paul L. Colbert and Bryant G. Wieking for
technical assistance.

CONFLICTS OF INTEREST
The authors have no conflicts of interest to report.

GRANT SUPPORT
This work was supported by Sanford Research, the
Molecular Pathology Core (funded by NIH CoBRE grant
24205

Oncotarget

P20GM103548-02), the Imaging Core (funded by NIH
CoBRE grant 5P20GM103620) ,NIH K08CA149078
(WCS), 1R01CA193522 (JHL), 5P20GM103548 (PDV).

11. Williams R, Lee DW, Elzey BD, Anderson ME,
Hostager BS, Lee JH. Preclinical models of HPV+ and
HPV- HNSCC in mice: an immune clearance of HPV+
HNSCC. Head & neck. 2009; 31:911–8. doi: 10.1002/
hed.21040. PMID: 19283850.

REFERENCES

12. Junttila MR, de Sauvage FJ. Influence of tumour microenvironment heterogeneity on therapeutic response. Nature.
2013; 501:346–54. doi: 10.1038/nature12626. PMID:
24048067.

1. Kademani D. Oral cancer. Mayo Clinic proceedings. 2007;
82:878–87. doi: 10.4065/82.7.878. PMID: 17605971.

13. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour
heterogeneity in the clinic. Nature. 2013; 501:355–64. doi:
10.1038/nature12627. PMID: 24048068.

2. Rogers SN, Brown JS, Woolgar JA, Lowe D, Magennis P,
Shaw RJ, Sutton D, Errington D, Vaughan D. Survival
following primary surgery for oral cancer. Oral oncology.
2009; 45:201–11. doi: 10.1016/j.oraloncology.2008.05.008.
PMID: 18674959.

14. Brabletz T, Lyden D, Steeg PS, Werb Z. Roadblocks to
translational advances on metastasis research. Nature
medicine. 2013; 19:1104–9. doi: 10.1038/nm.3327. PMID:
24013756; PMCID: PMC3972758.

3. Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of
HPV-associated oropharyngeal cancer. Oral oncology. 2014;
50:380–6. doi: 10.1016/j.oraloncology.2013.12.019. PMID:
24461628.

15. Hoover AC, Spanos WC, Harris GF, Anderson ME,
Klingelhutz AJ, Lee JH. The role of human papillomavirus
16 E6 in anchorage-independent and invasive growth of
mouse tonsil epithelium. Archives of otolaryngology—
head & neck surgery. 2007; 133:495–502. doi: 10.1001/
archotol.133.5.495.
PMID:
17515506;
PMCID:
PMC2917346.

4. Prince A, Aguirre-Ghizo J, Genden E, Posner M, Sikora A.
Head and neck squamous cell carcinoma: new translational
therapies. The Mount Sinai journal of medicine, New
York. 2010; 77:684–99. doi: 10.1002/msj.20216. PMID:
21105129.

16. Spanos WC, Hoover A, Harris GF, Wu S, Strand GL,
Anderson ME, Klingelhutz AJ, Hendriks W, Bossler AD,
Lee JH. The PDZ binding motif of human papillomavirus
type 16 E6 induces PTPN13 loss, which allows anchorageindependent growth and synergizes with ras for invasive
growth. Journal of virology. 2008; 82:2493–500. doi:
10.1128/JVI.02188-07. PMID: 18160445; PMCID:
PMC2258903.

5. Forastiere AA. Management of advanced stage squamous
cell carcinoma of the head and neck. The American
journal of the medical sciences. 1986; 291:405–15. PMID:
3521275.
6. McBride SM, Busse PM, Clark JR, Wirth LJ,
Ancukiewicz M, Chan AW. Long-term survival after
distant metastasis in patients with oropharyngeal
cancer. Oral oncology. 2014; 50:208–12. doi: 10.1016/j.
oraloncology.2013.10.020. PMID: 24387975.

17. Tremmel SC, Gotte K, Popp S, Weber S, Hormann K,
Bartram CR, Jauch A. Intratumoral genomic heterogeneity
in advanced head and neck cancer detected by comparative
genomic hybridization. Cancer genetics and cytogenetics.
2003; 144:165–74. PMID: 12850380.

7. Talmadge JE, Fidler IJ. AACR centennial series: the
biology of cancer metastasis: historical perspective. Cancer
research. 2010; 70:5649–69. doi: 10.1158/0008-5472.CAN10-1040. PMID: 20610625; PMCID: PMC4037932.

18. Slootweg PJ, Giessen MC, Rutgers DH, Wils IS. DNA
heterogeneity in metastasizing squamous cell head and
neck cancer. Journal of cranio-maxillo-facial surgery. 1993;
21:348–50. PMID: 8113428.

8. Hanahan D, Weinberg RA. Hallmarks of cancer: the
next generation. Cell. 2011; 144:646–74. doi: 10.1016/j.
cell.2011.02.013. PMID: 21376230.
9. Peinado H, Aleckovic M, Lavotshkin S, Matei I, CostaSilva B, Moreno-Bueno G, Hergueta-Redondo M,
Williams C, Garcia-Santos G, Ghajar C, NitadoriHoshino A, Hoffman C, Badal K, et al. Melanoma
exosomes educate bone marrow progenitor cells toward a
pro-metastatic phenotype through MET. Nature medicine.
2012; 18:883–91. doi: 10.1038/nm.2753. PMID: 22635005;
PMCID: PMC3645291.

19. Sewell A, Brown B, Biktasova A, Mills GB, Lu Y,
Tyson DR, Issaeva N, Yarbrough WG. Reverse-phase
protein array profiling of oropharyngeal cancer and
significance of PIK3CA mutations in HPV-associated
head and neck cancer. Clinical cancer research. 2014;
20:2300–11. doi: 10.1158/1078-0432.CCR-13-2585. PMID:
24599934; PMCID: PMC4027970.
20. Nguyen DX, Massague J. Genetic determinants of cancer
metastasis. Nature reviews Genetics. 2007; 8:341–52. doi:
10.1038/nrg2101. PMID: 17440531.

10. Muller A, Homey B, Soto H, Ge N, Catron D,
Buchanan ME, McClanahan T, Murphy E, Yuan W,
Wagner SN, Barrera JL, Mohar A, Verastegui E, et al.
Involvement of chemokine receptors in breast cancer
metastasis. Nature. 2001; 410:50–6. doi: 10.1038/35065016.
PMID: 11242036.
www.impactjournals.com/oncotarget

21. Spanos WC, Nowicki P, Lee DW, Hoover A, Hostager B,
Gupta A, Anderson ME, Lee JH. Immune response
during therapy with cisplatin or radiation for human
papillomavirus-related head and neck cancer. Archives of
24206

Oncotarget

otolaryngology—head & neck surgery. 2009; 135:1137–46.
doi: 10.1001/archoto.2009.159. PMID: 19917928.

and neck squamous cell carcinoma. International journal of
cancer. 2014; 134:2755–63. doi: 10.1002/ijc.28411. PMID:
23913554.

22. Ruzevick J, Olivi A, Westra WH. Metastatic squamous
cell carcinoma to the brain: an unrecognized pattern of
distant spread in patients with HPV-related head and neck
cancer. Journal of neuro-oncology. 2013; 112:449–54. doi:
10.1007/s11060-013-1075-9. PMID: 23408186; PMCID:
PMC3630253.

31. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell.
2000; 100:57–70. PMID: 10647931.
32. Hoover AC, Strand GL, Nowicki PN, Anderson ME,
Vermeer PD, Klingelhutz AJ, Bossler AD, Pottala JV,
Hendriks WJ, Lee JH. Impaired PTPN13 phosphatase
activity in spontaneous or HPV-induced squamous cell
carcinomas potentiates oncogene signaling through the
MAP kinase pathway. Oncogene. 2009; 28:3960–70.
doi: 10.1038/onc.2009.251. PMID: 19734941; PMCID:
PMC2785129.

23. Zhang XC, Xu C, Mitchell RM, Zhang B, Zhao D,
Li Y, Huang X, Fan W, Wang H, Lerma LA, Upton MP,
Hay A, Mendez E, et al. Tumor evolution and intratumor
heterogeneity of an oropharyngeal squamous cell carcinoma
revealed by whole-genome sequencing. Neoplasia. 2013;
15:1371–8. PMID: 24403859; PMCID: PMC3884528.

33. Vermeer PD, Bell M, Lee K, Vermeer DW, Wieking BG,
Bilal E, Bhanot G, Drapkin RI, Ganesan S, Klingelhutz AJ,
Hendriks WJ, Lee JH. ErbB2, EphrinB1, Src kinase
and PTPN13 signaling complex regulates MAP kinase
signaling in human cancers. PloS one. 2012; 7:e30447. doi:
10.1371/journal.pone.0030447. PMID: 22279592; PMCID:
PMC3261204.

24. Lopez-Gomez M, Moreno-Rubio J, Suarez-Garcia I, Cejas P,
Madero R, Casado E, Jimenez AM, Sereno M, GomezRaposo C, Zambrana F, Merino M, Fernandez-Luengas D,
Feliu J. Gene expression differences in primary colorectal
tumors and matched liver metastases: chemotherapy related
or tumoral heterogeneity? Clinical & translational oncology.
2015; 17:322–9. doi: 10.1007/s12094-014-1233-3.

34. Vermeer PD, Colbert PL, Wieking BG, Vermeer DW,
Lee JH. Targeting ERBB receptors shifts their partners and
triggers persistent ERK signaling through a novel ERBB/
EFNB1 complex. Cancer research. 2013; 73:5787–97.
doi: 10.1158/0008-5472.CAN-13-0760. PMID: 23811940;
PMCID: PMC4048035.

25. Brodsky AS, Fischer A, Miller DH, Vang S, MacLaughlan S,
Wu HT, Yu J, Steinhoff M, Collins C, Smith PJ, Raphael BJ,
Brard L. Expression profiling of primary and metastatic
ovarian tumors reveals differences indicative of aggressive
disease. PloS one. 2014; 9:e94476. doi: 10.1371/journal.
pone.0094476. PMID: 24732363; PMCID: PMC3986100.

35. Coppock JD, Wieking BG, Molinolo AA, Gutkind JS,
Miskimins WK, Lee JH. Improved clearance during
treatment of HPV-positive head and neck cancer through
mTOR inhibition. Neoplasia. 2013; 15:620–30. PMID:
23730210; PMCID: PMC3664994.

26. Takes RP, Rinaldo A, Silver CE, Haigentz M, Jr.,
Woolgar JA, Triantafyllou A, Mondin V, Paccagnella D, de
Bree R, Shaha AR, Hartl DM, Ferlito A. Distant metastases
from head and neck squamous cell carcinoma. Part I. Basic
aspects. Oral oncology. 2012; 48:775–9. doi: 10.1016/j.
oraloncology.2012.03.013. PMID: 22520054.

36. Vermeer DW, Spanos WC, Vermeer PD, Bruns AM,
Lee KM, Lee JH. Radiation-induced loss of cell surface
CD47 enhances immune-mediated clearance of human
papillomavirus-positive cancer. International journal of
cancer. 2013; 133:120–9. doi: 10.1002/ijc.28015. PMID:
23292955; PMCID: PMC3972896.

27. Geurts TW, Balm AJ, van Velthuysen ML, van Tinteren H,
Burgers JA, van Zandwijk N, Klomp HM. Survival after
surgical resection of pulmonary metastases and second
primary squamous cell lung carcinomas in head and neck
cancer. Head & neck. 2009; 31:220–6. doi: 10.1002/
hed.20952. PMID: 18972427.

37. Spanos WC, Geiger J, Anderson ME, Harris GF,
Bossler AD, Smith RB, Klingelhutz AJ, Lee JH. Deletion of
the PDZ motif of HPV16 E6 preventing immortalization and
anchorage-independent growth in human tonsil epithelial
cells. Head & neck. 2008; 30:139–47. doi: 10.1002/
hed.20673. PMID: 17657785; PMCID: PMC2600880.

28. Yamano Y, Uzawa K, Saito K, Nakashima D, Kasamatsu A,
Koike H, Kouzu Y, Shinozuka K, Nakatani K, Negoro K,
Fujita S, Tanzawa H. Identification of cisplatin-resistance
related genes in head and neck squamous cell carcinoma.
International journal of cancer. 2010; 126:437–49. doi:
10.1002/ijc.24704. PMID: 19569180.

38. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C,
Oksvold P, Mardinoglu A, Sivertsson A, Kampf C,
Sjostedt E, Asplund A, Olsson I, Edlund K, Lundberg E,
et al. Proteomics. Tissue-based map of the human proteome.
Science. 2015; 347:1260419. doi: 10.1126/science.1260419.
PMID: 25613900.

29. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and
neck cancer. Lancet. 2008; 371:1695–709. doi: 10.1016/
S0140-673660728-X. PMID: 18486742.
30. Andersen AS, Koldjaer Solling AS, Ovesen T, Rusan M.
The interplay between HPV and host immunity in head

www.impactjournals.com/oncotarget

24207

Oncotarget

